Flexiseq™ Max Strength Wins Highly Commended In The Most Val...| MENAFN.COM

Thursday, 01 December 2022 03:44 GMT

Flexiseq™ Max Strength Wins Highly Commended In The Most Valuable Product Awards 2022


(MENAFN- GlobeNewsWire - Nasdaq)

PRESS RELEASE

FlexiSEQ M ax S trength wins H ighly C ommended in the M ost Valuable P roduct A wards 2022

LONDON, 25 November 202 2 – Ascension Healthcare plc (“Ascension” or the“Company”), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapies for haemophilia and osteoarthritis, today announces that FlexiSEQ™ Max Strength has won Highly Commended in the category of Joint & Muscular Pain at the Most Valuable Product (MVP) Awards 2022.

The MVP Awards are annual awards run by the pharmacy magazines P3Pharmacy, Pharmacy Magazine and Training Matters that recognise the most valuable products in 26 categories. The awards were voted on by an esteemed industry expert panel and Pharmacists and support staff at the UK National Pharmacy Show which took place in Birmingham in October. A celebratory gala lunch is taking place in London later today for award winners.

FlexiSEQ Max Strength is Ascension Healthcare's over the counter, drug-free, joint lubricating, pain relief product containing proprietary Sequessome Technology™ for people with joints affected by osteoarthritis.

Biresh Roy , Chief Executive Officer at Ascension comment ed :“Joint pain and stiffness is a hugely debilitating condition which affects millions of people globally every year. Receiving this award for FlexiSEQ Max Strength demonstrates how highly regarded our product is by our customers and the healthcare professionals that serve them.”

- Ends -

MENAFN25112022004107003653ID1105232450


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.